BRPI1007005A2 - anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 - Google Patents

anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6

Info

Publication number: BRPI1007005A2
Authority: BR; Brazil
Prior art keywords: isolated; antibody; vector; nucleic acid; pharmaceutical composition
Prior art date: 2009-01-29

Application number

BRPI1007005A

Other languages

English (en)

Inventor

Anthony Coyle

Bahija Jallal

Herren Wu

Michael Bowen

Peter Kiener

William Dall Acqua

Original Assignee

Medimmune Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-29

Filing date

2010-01-29

Publication date

2016-03-22

2010-01-29 Application filed by Medimmune Llc filed Critical Medimmune Llc

2016-03-22 Publication of BRPI1007005A2 publication Critical patent/BRPI1007005A2/pt

Links

150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)

BRPI1007005A 2009-01-29 2010-01-29 anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 BRPI1007005A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14810609P	2009-01-29	2009-01-29
US18418209P	2009-06-04	2009-06-04
PCT/US2010/022478 WO2010088444A1 (en)	2009-01-29	2010-01-29	Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

Publications (1)

Publication Number	Publication Date
BRPI1007005A2 true BRPI1007005A2 (pt)	2016-03-22

Family

ID=42396023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007005A BRPI1007005A2 (pt)	2009-01-29	2010-01-29	anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6

Country Status (14)

Country	Link
US (3)	US20120034212A1 (pt)
EP (1)	EP2391384A4 (pt)
JP (3)	JP2012516158A (pt)
KR (1)	KR20110108398A (pt)
CN (2)	CN104119438A (pt)
AU (1)	AU2010208125B2 (pt)
BR (1)	BRPI1007005A2 (pt)
CA (1)	CA2749200A1 (pt)
HK (1)	HK1201847A1 (pt)
MX (1)	MX337590B (pt)
RU (2)	RU2011135422A (pt)
SG (3)	SG10201704214VA (pt)
WO (1)	WO2010088444A1 (pt)
ZA (2)	ZA201104796B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200831528A (en)	2006-11-30	2008-08-01	Astrazeneca Ab	Compounds
MX337590B (es) *	2009-01-29	2016-03-11	Medimmune Llc	Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
WO2010100135A1 (en)	2009-03-05	2010-09-10	Ablynx N.V.	Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en)	2009-03-05	2016-02-23	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
PL3438126T3 (pl) *	2009-09-03	2021-03-08	Ablynx N.V.	Stabilne formulacje polipeptydów i ich zastosowanie
CN103261222B (zh) *	2010-09-10	2017-07-28	医疗免疫有限公司	抗体衍生物
US9505826B2 (en) *	2010-12-22	2016-11-29	Teva Pharmaceuticals Australia Pty Ltd	Modified antibody with improved half-life
SI2673294T1 (sl)	2011-02-10	2016-08-31	Roche Glycart Ag	Mutirani polipeptidi interlevkina-2
MX342810B (es)	2011-03-03	2016-10-13	Apexigen Inc	Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN110655578A (zh)	2011-09-30	2020-01-07	中外制药株式会社	诱导针对靶抗原的免疫应答的抗原结合分子
WO2013047748A1 (ja)	2011-09-30	2013-04-04	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140335089A1 (en)	2011-09-30	2014-11-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting elimination of antigens
CN107266564A (zh)	2012-02-24	2017-10-20	中外制药株式会社	经由FcγIIB促进抗原消除的抗原结合分子
WO2013175276A1 (en)	2012-05-23	2013-11-28	Argen-X B.V	Il-6 binding molecules
EP2722341B1 (en)	2012-10-22	2017-12-06	Fountain Biopharma Inc.	Antibodies to interleukin-6 and uses thereof
EP2911693A4 (en) *	2012-10-25	2016-04-27	Medimmune Llc	STABLE, LOW-VISIC ANTIBODY FORMULATION
US10772940B1 (en) *	2012-12-11	2020-09-15	University Of Kentucky Research Foundation	Cocaine hydrolase-FC fusion proteins for ***e and methods for utilizing the same
FR2999431B1 (fr) *	2012-12-17	2016-03-18	Lfb Biotechnologies	Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US20160185847A1 (en) *	2012-12-17	2016-06-30	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
MX2016005686A (es) *	2013-10-31	2016-08-11	Regeneron Pharma	Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
PT3215530T (pt)	2014-11-07	2019-11-21	Sesen Bio Inc	Anticorpos de il-6 melhorados
AU2016302768B2 (en)	2015-07-31	2019-08-22	Medimmune Limited	Methods for treating hepcidin-mediated disorders
JP2019510078A (ja) *	2016-02-23	2019-04-11	セセンバイオ，インコーポレイテッド	Ｉｌ−６アンタゴニスト製剤およびその使用
WO2017177032A2 (en) *	2016-04-07	2017-10-12	Janssen Biotech, Inc.	Treatment of depression using agents that block binding of il-6 to il-6 receptor
CA3051865C (en) *	2017-02-01	2023-01-17	Yale University	Treatment of diuretic resistance
US20190241650A1 (en) *	2018-01-05	2019-08-08	Corvidia Therapeutics, Inc.	Methods for treating il-6 mediated inflammation without immunosuppression
WO2020023644A2 (en)	2018-07-24	2020-01-30	Medimmune, Llc	Antibody directed against s. aureus clumping factor a (clfa)
TW202028232A (zh)	2018-10-09	2020-08-01	美商麥迪紐有限責任公司	針對金黃色葡萄球菌白血球毒素的抗體
AU2019357983A1 (en)	2018-10-09	2021-05-27	Medimmune, Llc	Combinations of anti-staphylococcus aureus antibodies
WO2020185986A1 (en)	2019-03-13	2020-09-17	Medimmune, Llc	Decreasing staphylococcus aureus infections in colonized patients
MA55809A (fr)	2019-05-01	2022-03-09	Novo Nordisk As	Formulation d'anticorps anti-il-6
CN111057152B (zh) *	2019-12-11	2022-03-11	中国人民解放军第四军医大学	一种抗人IL-6Ra单克隆抗体及其应用
US20230293636A1 (en) *	2019-12-31	2023-09-21	Peptinov	Pharmaceutical composition for the prevention or treatment of post-surgical pain
WO2021186398A1 (en)	2020-03-19	2021-09-23	Medimmune Limited	Anti-klebsiella pneumoniae antibodies and uses thereof
US20210355196A1 (en)	2020-05-17	2021-11-18	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of selecting and using the same
AR122933A1 (es)	2020-07-10	2022-10-19	Novo Nordisk As	Métodos para tratar la enfermedad cardiovascular
CN116234577A (zh)	2020-08-10	2023-06-06	阿斯利康(英国)有限公司	用于治疗和预防covid-19的sars-cov-2抗体
TW202342095A (zh)	2021-11-05	2023-11-01	英商阿斯特捷利康英國股份有限公司	用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023209177A1 (en)	2022-04-29	2023-11-02	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of using the same
WO2024073718A1 (en) *	2022-09-30	2024-04-04	Sonnet BioTherapeutics, Inc.	Low dose il-6 formulations and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69937994T2 (de) *	1998-03-17	2008-12-24	Chugai Seiyaku K.K.	Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
US7658921B2 (en) *	2000-12-12	2010-02-09	Medimmune, Llc	Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) *	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
KR20100120246A (ko) *	2001-11-14	2010-11-12	센토코 오르토 바이오테크 인코포레이티드	항 ｉｌ-6 항체, 조성물, 방법 및 용도
ATE328906T1 (de) *	2002-06-28	2006-06-15	Domantis Ltd	Dual-specifische liganden mit erhöhter halbwertszeit
SI2335725T1 (sl) *	2003-04-04	2017-01-31	Genentech, Inc.	Visokokoncentrirane formulacije protiteles in proteinov
WO2006050166A2 (en) *	2004-10-29	2006-05-11	Medimmune, Inc.	Methods of preventing and treating rsv infections and related conditions
PE20061324A1 (es) *	2005-04-29	2007-01-15	Centocor Inc	Anticuerpos anti-il-6, composiciones, metodos y usos
US8163881B2 (en) *	2005-05-31	2012-04-24	The Board Of Regents Of The University Of Texas System	Immunoglobulin molecules with improved characteristics
EP1899477A4 (en) *	2005-07-01	2010-01-20	Medimmune Inc	INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS
US20080071063A1 (en) *	2006-02-03	2008-03-20	Medimmune, Inc.	Protein Formulations
CA2644405A1 (en) *	2006-03-13	2007-09-20	Ablynx N.V.	Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
TW200831528A (en) *	2006-11-30	2008-08-01	Astrazeneca Ab	Compounds
AR064826A1 (es) *	2007-01-09	2009-04-29	Wyeth Corp	Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
US20080279851A1 (en) *	2007-05-07	2008-11-13	Medlmmune, Llc	Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ597767A (en) *	2007-05-21	2013-06-28	Bristol Myers Squibb Co	Antibodies to IL-6 and use thereof
WO2009002521A2 (en) *	2007-06-25	2008-12-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
KR20100049568A (ko) *	2007-06-26	2010-05-12	메디뮨 엘엘씨	Ｒｓｖ 감염 및 관련 병증의 치료 방법
MX337590B (es) *	2009-01-29	2016-03-11	Medimmune Llc	Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.

2010
- 2010-01-29 MX MX2011007832A patent/MX337590B/es active IP Right Grant
- 2010-01-29 EP EP10736433A patent/EP2391384A4/en not_active Ceased
- 2010-01-29 JP JP2011548315A patent/JP2012516158A/ja active Pending
- 2010-01-29 AU AU2010208125A patent/AU2010208125B2/en active Active
- 2010-01-29 WO PCT/US2010/022478 patent/WO2010088444A1/en active Application Filing
- 2010-01-29 CA CA2749200A patent/CA2749200A1/en not_active Abandoned
- 2010-01-29 CN CN201410349897.9A patent/CN104119438A/zh active Pending
- 2010-01-29 RU RU2011135422/10A patent/RU2011135422A/ru not_active Application Discontinuation
- 2010-01-29 CN CN2010800103915A patent/CN102387814A/zh active Pending
- 2010-01-29 SG SG10201704214VA patent/SG10201704214VA/en unknown
- 2010-01-29 US US13/146,278 patent/US20120034212A1/en not_active Abandoned
- 2010-01-29 BR BRPI1007005A patent/BRPI1007005A2/pt not_active Application Discontinuation
- 2010-01-29 KR KR1020117019221A patent/KR20110108398A/ko not_active Application Discontinuation
- 2010-01-29 SG SG2011046265A patent/SG172354A1/en unknown
- 2010-01-29 SG SG2014007637A patent/SG2014007637A/en unknown
- 2010-01-29 RU RU2015150249A patent/RU2650594C1/ru active
2011
- 2011-06-28 ZA ZA2011/04796A patent/ZA201104796B/en unknown
2012
- 2012-09-18 HK HK15102182.7A patent/HK1201847A1/xx unknown
- 2012-09-27 ZA ZA2012/07249A patent/ZA201207249B/en unknown
2014
- 2014-04-15 US US14/253,161 patent/US20140302058A1/en not_active Abandoned
2015
- 2015-06-19 JP JP2015123389A patent/JP2016019517A/ja active Pending
2016
- 2016-12-02 US US15/368,499 patent/US20170101468A1/en not_active Abandoned
2017
- 2017-06-07 JP JP2017112163A patent/JP2017206519A/ja active Pending

Also Published As

Publication number	Publication date
HK1201847A1 (en)	2015-09-11
RU2011135422A (ru)	2013-03-10
CN102387814A (zh)	2012-03-21
SG10201704214VA (en)	2017-06-29
CN104119438A (zh)	2014-10-29
AU2010208125A1 (en)	2011-07-21
US20140302058A1 (en)	2014-10-09
JP2012516158A (ja)	2012-07-19
ZA201104796B (en)	2018-11-28
ZA201207249B (en)	2013-08-28
EP2391384A4 (en)	2012-12-26
MX337590B (es)	2016-03-11
CA2749200A1 (en)	2010-08-05
JP2017206519A (ja)	2017-11-24
AU2010208125B2 (en)	2015-02-12
SG172354A1 (en)	2011-07-28
KR20110108398A (ko)	2011-10-05
US20170101468A1 (en)	2017-04-13
SG2014007637A (en)	2014-03-28
US20120034212A1 (en)	2012-02-09
WO2010088444A1 (en)	2010-08-05
EP2391384A1 (en)	2011-12-07
JP2016019517A (ja)	2016-02-04
RU2650594C1 (ru)	2018-04-17
MX2011007832A (es)	2011-10-06

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-18	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-02-27	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-11-17	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
BRPI1007005A2 (pt)	2016-03-22	anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
BRPI0909044A2 (pt)	2017-05-30	anticorpo, sequência de ácidos nucleicos, vetor, composição farmacêutica, kit de partes, e, uso de um anticorpo, uma sequência de ácidos nucléicos, um vetor, uma composição farmacêutica ou um kit de partes
BR112014016076A8 (pt)	2017-07-04	peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112012006326A2 (pt)	2016-11-16	anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BR112013018311A2 (pt)	2017-03-21	sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
BRPI0914691A2 (pt)	2015-10-20	composto imunoadjuvante, composição, uso de um composto imunoadjuvante, ácido nucléico, vetor recombinante, e, célula hospedeira
BR112013033350A2 (pt)	2017-01-31	imunocitocina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
BRPI0924177A2 (pt)	2015-08-18	Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI1006368A2 (pt)	2016-10-25	proteína de fusão. molécula de ácido nucleico, vetor, célula modificada geneticamente, método para produção da proteína de fusão, usos da proteína de fusão, composição, método para preparação de uma composição, kits, método e uso da proteína de fusão
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BR112014017518A8 (pt)	2017-07-04	anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
BRPI0817265A2 (pt)	2015-06-16	Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
BR112014012624A2 (pt)	2018-10-09	anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BR112012026174A2 (pt)	2019-09-24	anticorpo isolado, ácido nucleico isolado, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, doença ou disfunção, uso do anticorpo, método de tratamento, de determinação e de separação
BRPI0915137A2 (pt)	2016-02-16	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica